Table 2 Incidence and rated severity of key neuropathological changes across area deprivation groups
1—least deprived N = 293 | 2 N = 209 | 3 N = 142 | 4 N = 77 | 5—most deprived N = 68 | ||
|---|---|---|---|---|---|---|
Alzheimer’s Disease Neuropathological Change | ||||||
Thal Amyloid Phase | 4 [1, 5] | 3 [1, 5] | 3 [1, 5] | 3 [1, 4] | 4 [2, 5] | |
Braak Tangle Stage | 4 [2, 5] | 3 [2, 6] | 3 [2, 5] | 3 [2, 5] | 5 [3, 6] | |
CERAD Plaque Score | 2 [0, 3] | 2 [0, 3] | 1 [0, 3] | 1 [0, 3] | 2 [1, 3] | |
Lewy Body Disease | ||||||
Any LB Disease | 94 (32.1%) | 63 (30.1%) | 35 (24.6%) | 19 (24.7%) | 22 (32.4%) | |
Braak LB Stage | 0 [0, 3] | 0 [0, 4] | 0 [0, 0] | 0 [0, 1] | 0 [0, 3] | |
Amygdala LBs | 17 (5.8%) | 8 (3.8%) | 6 (4.2%) | 2 (2.6%) | 2 (2.9%) | |
Limbic LBs | 13 (4.4%) | 16 (7.7%) | 8 (5.6%) | 4 (5.2%) | 6 (8.8%) | |
Brainstem LBs | 6 (2.0%) | 2 (1.0%) | 4 (2.8%) | 1 (1.3%) | 0 (0%) | |
Neocortical LBs | 32 (10.9%) | 16 (7.7%) | 8 (5.6%) | 5 (6.5%) | 5 (7.4%) | |
Cerebrovascular Disease | ||||||
Infarct(s) > 10 mm | 33 (11.3%) | 15 (7.2%) | 13 (9.2%) | 6 (7.8%) | 9 (13.2%) | |
Moderate/severe CAA | 86 (29.4%) | 66 (31.6%) | 38 (26.8%) | 23 (29.9%) | 27 (39.7%) | |
Moderate/Severe WM Arteriosclerosis | 71 (24.2%) | 40 (19.1%) | 30 (21.1%) | 11 (14.3%) | 12 (17.6%) | |
TDP-43 Pathology | ||||||
LATE-NC | 79 (27.0%) | 45 (21.5%) | 27 (19.0%) | 16 (20.8%) | 15 (22.1%) | |
FTLD-TDP | 2 (0.6%) | 4 (2.0%) | 1 (0.7%) | 3 (3.9%) | 1 (1.5%) | |
Not Assessed | 25 (8.5%) | 6 (2.9%) | 10 (7.0%) | 1 (1.3%) | 1 (1.5%) | |
Other Findings | ||||||
Any FTLD | 8 (2.7%) | 6 (2.9%) | 5 (3.5%) | 4 (5.2%) | 4 (5.9%) | |
Corticobasal Degeneration | 2 (0.7%) | 2 (1.0%) | 0 (0%) | 0 (0%) | 2 (2.9%) | |
Argyrophilic Grain Disease | 6 (2.0%) | 5 (2.4%) | 2 (1.4%) | 1 (1.3%) | 1 (1.5%) | |